Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06988462 · ClinicalTrials.gov registry record · NA
Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
A NA study of Diabetes and PreDiabetes, sponsored by Cambridge Health Alliance.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06988462: Recruiting NA study of Diabetes and PreDiabetes, sponsored by Cambridge Health Alliance.
NCT06988462 is a NA study of Diabetes and PreDiabetes that is actively recruiting participants, run by Cambridge Health Alliance. The registered enrollment target is 20 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06988462, a NA study of Diabetes and PreDiabetes, is actively recruiting participants, sponsored by Cambridge Health Alliance.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study aims to explore the potential benefits of consuming Greek bottarga (grey mullet fish roe) in individuals with at least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides, obesity, or HbA1c ≥ 5.7%) or a diagnosis of diabetes. Before initiating the crossover randomized controlled trial (RCT), the investigators will conduct a preliminary dose-testing study in five adults with at least one metabolic abnormality. Participants will undergo clinical assessments before and after the dietary intervention to evaluate changes in metabolic health markers. Following this phase, the investigators will proceed with a randomized, controlled crossover trial involving 20 eligible adult participants. This main study phase will compare the metabolic effects of daily bottarga supplementation with those of a calorically matched dairy product over an 8-week intervention period, with a 2-week washout period between interventions. The investigators anticipate that bottarga supplementation will improve lipid profiles, inflammation markers, and insulin resistance, thereby supporting the potential use of sustainable blue foods as part of a healthy diet.
Primary Outcome
Mean change in fasting glucose levels (mg/dL) after overnight fast.
Conditions Studied
Interventions
- OTHER Bottarga
- OTHER Comparator
Study Locations (1)
Massachusetts
- Cambridge Health Alliance - Sommerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-10-17 |
| Est. Completion | 2026-12-01 |
| Phase | NA |
What NCT06988462 shows while recruiting
NCT06988462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower).
The record links to 6 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Bottarga is the first listed.
NCT06988462 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06988462 about?
NCT06988462 is a clinical study titled "Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food". This pilot study aims to explore the potential benefits of consuming Greek bottarga (grey mullet fish roe) in individuals with at least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides, obesity, or HbA1c ≥ 5.7%) or a diagnosis of diabetes. Before initiating t...
What is the current status of trial NCT06988462?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-10-17. Estimated completion is 2026-12-01.
What conditions does trial NCT06988462 study?
This clinical trial studies the following conditions: Diabetes, PreDiabetes, Obesity & Overweight, Triglycerides, High Cholesterol/Hyperlipidemia.
What interventions are being tested in trial NCT06988462?
The interventions under investigation include: Bottarga (OTHER), Comparator (OTHER).
Who is sponsoring clinical trial NCT06988462?
This trial is sponsored by Cambridge Health Alliance, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06988462 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06988462's enrollment target sits among peer trials
20 305th of 338 higher than 25 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI